DJIA 18,011.94 -28.43 -0.16%
NASDAQ 5,076.52 -6.41 -0.13%
S&P 500 2,109.60 -2.13 -0.10%
market minute promo

Pfizer (NYSE: PFE)

34.49 -0.07 (-0.20%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PFE $34.49 -0.20%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.64
Previous Close $34.56
Daily Range $34.35 - $34.66
52-Week Range $27.51 - $35.53
Market Cap $212.4B
P/E Ratio 24.00
Dividend (Yield) $1.12 (3.2%)
Ex-Dividend Date
Dividend Pay Date
05/06/15
06/02/15
Volume 18,666,242
Average Daily Volume 24,129,585
Current FY EPS $2.04

Sector

Healthcare

Industry

Drug Makers

Pfizer (PFE) Description

A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra. Website: http://www.pfizer.com/

News & Commentary Rss Feed

Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.

AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.

Pfizer's (PFE) Management Reviews Oncology Business and ASCO Data Presentations (Transcript)

Why Health Care Stocks Will Continue to Lead Market Higher

Health care companies see $ signs as Baby Boomers age

Health care companies see dollar signs as Baby Boomers get older

Dow Jones (DJIA) Today: Pfizer (PFE) Lower

Pfizer's Monstrous Clinical Pipeline Is Harboring 2 Hidden Gems

Pfizer's mind-boggling size often results in promising clinical candidates getting swept under the rug, so to speak. Here is a look at two of the pharma giant's orphan drug candidates that haven't generated much talk among investors, despite being potential game-changers for their target indications.

10 American Companies That Pull in the Most Cash

Let's measure something that's better than "profitability."

Viagra Maker Pfizer Keeps Boosting Dividends

4 Stocks Eagle Asset Management Has Been Buying

It can pay off to keep an eye on what the big investors are doing.

Is A Big Acquisition Is Due For Pfizer?

See More PFE News...

PFE's Top Competitors

PFE $34.49 (-0.20%)
Current stock: PFE
ROG $72.75 (-0.29%)
Current stock: ROG
MRK $60.24 (-0.84%)
Current stock: MRK
JNJ $99.98 (-0.06%)
Current stock: JNJ